The potential of monoclonal antibodies in cancer: Established trastuzumab and cetuximab and promising targets IGF-IR and c-MET;Anticorps et tumeurs solides: Cibles établies et pistes prometteuses

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1090-1098

  Bodmer, Alexandre ^a   Goetsch, Liliane ^b   Favet, Laurence ^a   Bailly, Christian ^b   Corvaia, Nathalie ^b   Dietrich, Pierre Yves ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74749084437     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121090     Document Type: Review

References (41)

1. Hudis CA. Trastuzumab mechanism of action and use in clinical practice. N Engl J Med 2007 ; 357 : 39-51.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 ; 244 : 707-12.
3. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999 ; 17 : 2639-48.
4. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002 ; 20 : 719-26.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl Med 2001 ; 344 : 783-92.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1673-84.
7. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 ; 353 : 1659-72.
8. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in huma epidermal growth factor receptor 2-positive operable breast cancer : an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007 ; 13 : 228-33.
9. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspective in HER2-overexpressing breast cancer. Ann Oncol 2007 ; 18 : 977-84.
10. Van Custem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trials: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J Clin Oncol 2009 ; 27 : 18S (abstract LBA4509).
11. Ciordello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008 ; 358 : 1160-74.
12. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 ; 351 : 337-45.
13. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007 ; 357 : 2040-8.
14. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009 ; 360 : 1408-17.
15. ToI J, Koopman M, Cats A, Rodenburg CJ, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009 ; 360 : 563-72.
16. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006 ; 354 : 567-78.
17. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008 ; 359 : 1116-27.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008 ; 359 : 1757-65.
19. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986 ; 5 : 2503-12.
20. Soos MA, Siddle K. Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem J 1989 ; 263 : 553-63.
21. Kato H, Faria TN, Stannard B, et al. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol 1994 ; 8 : 40-50.
22. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts, Mol Cell Biol 1994 ; 14 : 3604-12.
23. Baserga R, Hongo A, Rubini M, et al. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1997 ; 1332 : F105-F126.
24. Lu y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001 ; 93 : 1852-7.
25. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008 ; 118 : 2609-19.
26. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts, lnt J Cancer 2005 ; 113 : 316-28.
27. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003 ; 63 : 8912-21.
28. Schnitzer T, Kuenkele KP, Rebers F, et al. Characterization of a recombinant, fully human monoclonal antibody directed against the human insulin-like growth factor-I receptor. Eur J Cancer 2006 ; 4 (suppl) : 66-7.
29. Beltran PJ, Mitchell P, Moody G, et al. AMG-479, a fully human anti IGF-I receptor antibody, inhibits PISK/Akt signaling and exerts potent antitumor effects in combination with EGFR inhibitors in pancreatic xenograft models. Orlando (FI-USA) : Gastrointestinal Cancers Symposium, 2007.
30. Loo D, Pryer N, Young P, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007 ; 6 : 856-65.
31. Wang Y, Hailey J, Williams D, et al. Inhibition of insulin-like growth factor-I receptor (IGFIR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005 ; 4 : 1214-21.
32. Hariharan K, Dong J, Demarest S, et al. BIIB022, a fully human nonglycosylated g4P antibody targeting IGF-IR for cancer therapy. Houston (TX-USA) : AACR Meeting Abstracts (3 Molecular Targets Meeting), 2007 : B210.
33. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition af tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005 ; 11 : 2063-73.
34. Resnicoff M. Antitumor effects elicited by antisense-mediated downregulation of the insulin-like growth factor I receptor, Int J Mol Med 1998 ; 1 : 883-8.
35. Sachdev D, Singh R, Fujita-Yamaguchi Y, Yee D. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006 ; 66 : 2391-2402.
36. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 ; 316 : 1039-43.
37. Shattuck DL, Miller JK, Carraway KL, III, Sweeney C. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 2008 ; 68 : 1471-7.
38. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008 ; 7 : 504-16.
39. Martens T, Schmidt NO, Eckerich C, et al. Novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo Clin Cancer Res 2006 ; 12 : 6144-52.
40. th Meeting, 2009 (abstract 2792).
41. th Meeting, 2009 (abstract 835).